Table 1.

Clinical and demographic characteristics of population enrolled.

	Total	Female	Male
N. Patients	775	417	358
Mean age, y (±SD)	56.0 (15.2)	55.4 (14.5)	56.6 (15.9)
Comorbidities	313 (40.39)	171 (41.00)	142 (39.66)
N. OF FOLLOW-UP
No follow-up	263 (33.93)	137 (32.85)	126 (35.20)
1 follow-up	128 (16.52)	72 (17.27)	56 (15.64)
2–5 follow-up	233 (30.06)	128 (30.70)	105 (29.33)
6-10 follow-up	75 (9.68)	41 (9.83)	34 (9.50)
> 10	76 (9.81)	39 (9.35)	37 (10.33)
Mean follow-up/patient (CI 95%)	3.48 (3.13–3.84)
CLINIC UNIT
Onco-hematology	432 (55.74)	214 (51.32)	218 (60.89)
Rheumatology	219 (28.26)	148 (35.50)	70 (19.55)
Hepato-gastroenterology	77 (9.94)	29 (6.95)	49 (13.69)
Dermatology	33 (4.26)	17 (4.07)	16 (4.47)
Neurology	14 (1.81)	9 (2.16)	5 (1.40)
DIAGNOSIS (N. %)
Hematological malignancies	155 (20.00)	60 (14.39)	95 (26.54)
Rheumatoid arthritis	130 (16.77)	106 (25.42)	24 (6.70)
Colorectal cancer	125 (16.13)	45 (10.79)	80 (22.35)
Breast cancer	88 (11.35)	86 (20.62)	2 (0.56)
Psoriatic arthritis	51 (6.58)	27 (6.47)	24 (6.70)
Crohn disease	41 (5.29)	20 (4.80)	21 (5.87)
Ulcerative colitis	36 (4.65)	8 (1.92)	28 (7.82)
Psoriasis	32 (4.13)	17 (4.08)	15 (4.19)
Spondylo-arthropathy	30 (3.87)	9 (2.16)	21 (5.87)
Head and neck cancer&	21 (2.71)	4 (0.96)	17 (4.75)
Lung cancer	19 (2.45)	5 (1.20)	14 (3.91)
Multiple sclerosis	14 (1.81)	9 (2.16)	5 (1.40)
Gastric cancer	12 (1.55)	4 (0.96)	8 (2.23)
Ovarian cancer	9 (1.16)	9 (2.16)	–
Systemic vasculitis	4 (0.52)	2 (0.48)	2 (0.56)
*SLE	2 (0.26)	2 (0.48)	–
Osteoporosis	2 (0.26)	2 (0.48)	–
Prostatic cancer	1 (0.13)	–	1 (0.28)
Peritoneal cancer	2 (0.26)	1 (0.24)	1 (0.28)
Missing diagnosis	1 (0.13)	1 (0.24)	–

^&Laryngeal cancer, Brain cancer, and oropharyngeal have been included.

^*SLE, Systemic lupus erythematosus.